C4 Therapeutics Q3 net loss widens to $32.0M; cash runway to end of 2024

C4 Therapeutics, Inc.

2022-Q3 EPS reported -$1.86 revenue$28,242,000

Net loss $32.0M ($0.65/diluted share) vs $24.7M ($0.51) in Q3 2021; revenue $6.8M vs $8.5M.
Cash, equivalents & marketable securities $366.0M at Sep 30, down from $451.5M at Dec 31, 2021; runway to end of 2024.
Phase 1/2 trials for CFT7455 (IKZF1/3 degrader in MM/NHL) and CFT8634 (BRD9 in synovial sarcoma) advancing dose escalation.
IND clearance for CFT1946 (BRAF-V600 degrader) in Sep; Phase 1/2 to initiate by year-end 2022.
Upcoming milestones: CFT8919 (EGFR L858R) IND-enabling activities to complete by year-end 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

C4 Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $6.8 million, net income $32.0 million, EPS $0.65.

Period: third quarter ended September 30, 2022
Revenue: $6.8 million
Net income: $32.0 million
EPS: $0.65
Result: reported results

Exact text from the filing

will participate in a fireside chat at the Evercore ISI HealthCONx Conference. THIRD QUARTER 2022 FINANCIAL RESULTS Revenue: Total revenue for the third quarter of 2022 was $6.8 million, compared to $8.5 million for the third quarter of 2021. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and

View on SEC.gov

Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.